KEYSIGHT TECHNOLOGIES, INC. (KEYS) valuation

  1. Home
  2. Financials
  3. KEYS
  4. Valuation
SEC pipeline catching up: most recent reported quarter (2026-04-30) isn't incorporated yet — this page is anchored to 2026-01-31 (Q1 2026 · 10-Q). New filings land within a few weekday pipeline runs.

Share price $216.33 · As of last filing 2026-01-31

Price-to-Earnings

P/E · Trailing Diluted
38.84×
P/E history →

Price-to-Earnings (Underlying)

P/E · Adjusted TTM Period gap
24.95×
Methodology →

Price-to-Free-Cash-Flow

P/FCF · Trailing
27.65×
P/FCF history →

Free-Cash-Flow Yield

FCF Yield · Trailing
3.62%
FCF Yield history →

Enterprise-Value-to-EBITDA

EV/EBITDA · Trailing
31.11×
EV/EBITDA history →

Price-to-Sales

P/S · Trailing
6.54×
P/S history →

Price-to-Book

P/B · Latest filing
5.98×
P/B history →

What these ratios mean & how they're built: see the valuation ratios glossary on the Financials methodology page — per-ratio definitions and the exact us-gaap concepts behind each numerator and denominator.

Sources. Denominators come from SEC EDGAR XBRL filings for KEYS (CIK 0001601046); analyst growth forecasts come from analyst consensus. Filing-anchored figures are rendered server-side at the split-adjusted close on the latest reported period-end — so every ratio reconciles to the same filing as every other figure on this page — and the share price, six ratio cards, EPV gap, and reverse-DCF outputs above re-anchor on the most recent daily close in the browser when JavaScript is enabled. The "Full calculation trail" sections stay anchored to the period-end close so the line-by-line arithmetic still reconciles. Per-share denominators are split-adjusted to today's share count.

Related tickers

CATX

PERSPECTIVE THERAPEUTICS, INC.

KODK

EASTMAN KODAK COMPANY

SNWV

SANUWAVE Health, Inc.